MRNA · Moderna Inc
United States · RS rating 99 · As of 2026-11-03
| Price | 228.44 USD |
|---|---|
| 1-day change | +3.5% |
| RS rating (overall / 1M / 3M / 12M) | 99 / 86 / 98 / 99 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 51 / 74 / 53 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -313.7% |
| Sales growth Q/Q | -32.5% |
| Distance from 52-week high | +7.1% |
| Market cap (USD) | $21.0B |